Investigating the effects of hydrogen water and minocycline on brain recovery after stroke
Official title: MRI Study of Hydrogen Water and Minocycline Combination Therapy for Ischemic Stroke
Funded at Albert Einstein College of Medicine · NIH-11001159 · Data updated 2026-11-12
This study is looking at how hydrogen water and a medication called minocycline might help the brain heal after a stroke, using rats to see how these treatments could improve brain health and recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $368,438 |
| NIH project number | 5R01NS129936-03 |
| Project ID | NIH-11001159 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals who have experienced an ischemic stroke and are seeking innovative treatment options.
✕Less likely to help
Patients who have not had a stroke or those with other neurological conditions unrelated to ischemic stroke may not benefit from this research.
What this research studies
This research explores how hydrogen water and minocycline, both known for their neuroprotective properties, can aid recovery after an ischemic stroke. Using advanced MRI techniques, the study aims to assess brain tissue viability and the effectiveness of these treatments in a rat model of stroke. The researchers will analyze how these therapies impact brain health and functional recovery over time, providing insights into potential new treatments for stroke patients.
Why it matters
Potential benefit: If successful, this research could lead to improved recovery strategies for stroke patients, potentially reducing brain damage and enhancing functional outcomes.
How similar studies have gone: Previous studies have shown promising results with hydrogen water and minocycline in neuroprotection, suggesting that this combined approach may also yield beneficial outcomes.
Where this research is happening
-
Albert Einstein College of Medicine
Bronx, United States Active
Researchers
- Principal investigator: Duong, Timothy Q. — Albert Einstein College of Medicine
- Study coordinator: Duong, Timothy Q.
Related research
Other NIH-funded projects on the same topics.
-
Improving blood flow after stroke by breaking down NETs
Aims to see if breaking down neutrophil extracellular traps (NETs) after an ischemic stroke can improve blood flow and reduce brain injury in patients.
-
EP2 blockers to protect the brain after a stroke
Aims to test brain-permeable EP2 antagonists to reduce damage after ischemic stroke and improve recovery.
-
Genetic testing to find causes of early-onset ischemic stroke
This project uses whole-exome sequencing to look for gene changes that may cause ischemic stroke in adults who had a stroke at a young age.
-
Targeted nanomedicine to protect the brain after stroke
A targeted drug-delivery approach aims to boost blood-brain barrier repair and reduce brain damage after an acute ischemic stroke in patients at risk.
-
How biological aging and blood proteins relate to thinking after a stroke
This project looks at whether measures of biological aging and patterns of blood proteins help explain which stroke survivors keep their thinking sharp and which go on to develop vascular dementia.
-
Repurposing NEXLETOL to treat ischemic stroke
Aims to see if the cholesterol drug NEXLETOL can help people after an ischemic stroke by supporting brain energy use and reducing injury.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.